DSM to Supply Cancer Drug for Eisai

DSM to Supply Cancer Drug for Eisai

By Dan Stanton

Eisai says its US supply agreement with DSM offers an alternate manufacturing facility and ensures a strengthened supply line.

Johnson Matthey aims to optimize API biz

Johnson Matthey to optimise API biz; Fine Chem forecasts roundup

By Gareth Macdonald presents a roundup of news in the fine chemicals sector, beginning with Johnson Matthey which has started a review of its active pharmaceutical ingredient (API) business after competition in the UK impacted its third quarter...

Italian drugmaker commits to ADC development

Menarini forms ADC manufacturing deal with OBT

By Gareth Macdonald

Menarini has committed millions of euros to an antibody drug conjugate (ADC) clinical development and manufacturing pact with Oxford BioTerapeutics (OBT). 

M&A, partnerships and new services in pharma outsourcing

New pharma services from M&A and partnerships: round-up

By Natalie Morrison presents the low down on new services forged by partnerships and M&A (mergers and acquisitions), including a molecular biology offering for Quotient, Onyx’s added purification and separation capabilities, and Accenture’s new...

Catalent continues to boost biologics offering

Catalent continues to boost biologics offering

By Natalie Morrison

Catalent has upgraded its North Carolina, US, sterile development and analytics plant to increase its aseptic fill-finish activities four-fold in a bid to boost its integrated biologics offering.